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Figure 2. Recommended immunization schedule for adults aged 19 years or older by medical condition and other indications, United States, 2017
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Figure 1. Recommended immunization schedule for adults aged 19 years or older by age group, United States, 2017
Vaccine 19–21 years 22–26 years 27–59 years 60–64 years ≥ 65 years
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Td/Tdap2
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HPV–Female6
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HepA8
HepB9
MenACWY or MPSV410
MenB10
Hib11
Figures 1 and 2 should be read with the footnotes that contain important general information and considerations for special populations.
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Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2017
1. Influenza vaccination
General information
• All persons aged 6 months or older who do not have a 
contraindication should receive annual influenza vaccination with an 
age-appropriate formulation of inactivated influenza vaccine (IIV) or 
recombinant influenza vaccine (RIV).
• In addition to standard-dose IIV, available options for adults in 
specific age groups include: high-dose or adjuvanted IIV for adults 
aged 65 years or older, intradermal IIV for adults aged 18 through 64 
years, and RIV for adults aged 18 years or older.
• Notes: Live attenuated influenza vaccine (LAIV) should not be used 
during the 2016–2017 influenza season. A list of currently available 
influenza vaccines is available at www.cdc.gov/flu/protect/vaccine/
vaccines.htm.
Special populations
• Adults with a history of egg allergy who have only hives after 
exposure to egg should receive age-appropriate IIV or RIV.
• Adults with a history of egg allergy other than hives, e.g., 
angioedema, respiratory distress, lightheadedness, or recurrent 
emesis, or who required epinephrine or another emergency medical 
intervention, may receive age-appropriate IIV or RIV. The selected 
vaccine should be administered in an inpatient or outpatient 
medical setting and under the supervision of a healthcare provider 
who is able to recognize and manage severe allergic conditions.
• Pregnant women and women who might become pregnant in the 
upcoming influenza season should receive IIV.
2. Tetanus, diphtheria, and acellular pertussis vaccination
General information
• Adults who have not received tetanus and diphtheria toxoids and 
acellular pertussis vaccine (Tdap) or for whom pertussis vaccination 
status is unknown should receive 1 dose of Tdap followed by a 
tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap 
should be administered regardless of when a tetanus or diphtheria 
toxoid-containing vaccine was last received.
• Adults with an unknown or incomplete history of a 3-dose primary 
series with tetanus and diphtheria toxoid-containing vaccines 
should complete the primary series that includes 1 dose of Tdap. 
Unvaccinated adults should receive the first 2 doses at least 4 weeks 
apart and the third dose 6–12 months after the second dose.
• Notes: Information on the use of Td or Tdap as tetanus prophylaxis in 
wound management is available at www.cdc.gov/mmwr/preview/
mmwrhtml/rr5517a1.htm.
Special populations
• Pregnant women should receive 1 dose of Tdap during each 
pregnancy, preferably during the early part of gestational weeks 
27–36, regardless of prior history of receiving Tdap.
3. Measles, mumps, and rubella vaccination
General information
• Adults born in 1957 or later without acceptable evidence of 
immunity to measles, mumps, or rubella (defined below) should 
receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless 
they have a medical contraindication to the vaccine, e.g., pregnancy 
or severe immunodeficiency.
• Notes: Acceptable evidence of immunity to measles, mumps, or 
rubella in adults is: born before 1957, documentation of receipt of 
MMR, or laboratory evidence of immunity or disease. Documentation 
of healthcare provider-diagnosed disease without laboratory 
confirmation is not acceptable evidence of immunity.
Special populations
• Pregnant women who do not have evidence of immunity to rubella 
should receive 1 dose of MMR upon completion or termination of 
pregnancy and before discharge from the healthcare facility; non-
pregnant women of childbearing age without evidence of rubella 
immunity should receive 1 dose of MMR.
• Adults with primary or acquired immunodeficiency including malignant 
conditions affecting the bone marrow or lymphatic system, systemic 
immunosuppressive therapy, or cellular immunodeficiency should not 
receive MMR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have 
evidence of measles, mumps, or rubella immunity should receive 2 
doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive MMR.
• Adults who work in healthcare facilities should receive 2 doses of MMR 
at least 28 days apart; healthcare personnel born before 1957 who are 
unvaccinated or lack laboratory evidence of measles, mumps, or rubella 
immunity, or laboratory confirmation of disease should be considered 
for vaccination with 2 doses of MMR at least 28 days apart for measles or 
mumps, or 1 dose of MMR for rubella.
• Adults who are students in postsecondary educational institutions or 
plan to travel internationally should receive 2 doses of MMR at least 28 
days apart.
• Adults who received inactivated (killed) measles vaccine or measles 
vaccine of unknown type during years 1963–1967 should be 
revaccinated with 1 or 2 doses of MMR.
• Adults who were vaccinated before 1979 with either inactivated mumps 
vaccine or mumps vaccine of unknown type who are at high risk for 
mumps infection, e.g., work in a healthcare facility, should be considered 
for revaccination with 2 doses of MMR at least 28 days apart.
4. Varicella vaccination
General information
• Adults without evidence of immunity to varicella (defined below) should 
receive 2 doses of single-antigen varicella vaccine (VAR) 4–8 weeks apart, 
or a second dose if they have received only 1 dose.
• Persons without evidence of immunity for whom VAR should be 
emphasized are: adults who have close contact with persons at high 
risk for serious complications, e.g., healthcare personnel and household 
contacts of immunocompromised persons; adults who live or work in 
an environment in which transmission of varicella zoster virus is likely, 
e.g., teachers, childcare workers, and residents and staff in institutional 
settings; adults who live or work in environments in which varicella 
transmission has been reported, e.g., college students, residents and 
staff members of correctional institutions, and military personnel; non-
pregnant women of childbearing age; adolescents and adults living in 
households with children; and international travelers.
• Notes: Evidence of immunity to varicella in adults is: U.S.-born before 
1980 (for pregnant women and healthcare personnel, U.S.-born before 
1980 is not considered evidence of immunity); documentation of 2 
doses of VAR at least 4 weeks apart; history of varicella or herpes zoster 
diagnosis or verification of varicella or herpes zoster disease by a 
healthcare provider; or laboratory evidence of immunity or disease.
Special populations
• Pregnant women should be assessed for evidence of varicella immunity. 
Pregnant women who do not have evidence of immunity should receive 
the first dose of VAR upon completion or termination of pregnancy and 
before discharge from the healthcare facility, and the second dose 4–8 
weeks after the first dose.
• Healthcare institutions should assess and ensure that all healthcare 
personnel have evidence of immunity to varicella.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive VAR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months 
apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 
cells/μl should not receive VAR.
5. Herpes zoster vaccination
General information
• Adults aged 60 years or older should receive 1 dose of herpes zoster 
vaccine (HZV), regardless of whether they had a prior episode of herpes 
zoster.
Special populations
• Adults aged 60 years or older with chronic medical conditions may 
receive HZV unless they have a medical contraindication, e.g., pregnancy 
or severe immunodeficiency.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive HZV.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive HZV.
6. Human papillomavirus vaccination
General information
• Adult females through age 26 years and adult males through age 21 
years who have not received any human papillomavirus (HPV) vaccine 
should receive a 3-dose series of HPV vaccine at 0, 1-2, and 6 months. 
Males aged 22 through 26 years may be vaccinated with a 3-dose series 
of HPV vaccine at 0, 1–2, and 6 months.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received 2 doses at least 5 months apart are considered adequately 
vaccinated and do not need an additional dose of HPV vaccine.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received only 1 dose, or 2 doses less than 5 months apart, are not 
considered adequately vaccinated and should receive 1 additional dose 
of HPV vaccine.
• Notes: HPV vaccination is routinely recommended for children at age 11 
or 12 years. For adults who had initiated but did not complete the HPV 
vaccination series, consider their age at first HPV vaccination (described 
above) and other factors (described below) to determine if they have 
been adequately vaccinated.
Special populations
• Men who have sex with men through age 26 years who have not 
received any HPV vaccine should receive a 3-dose series of HPV vaccine 
at 0, 1-2, and 6 months. 
• Adult females and males through age 26 years with 
immunocompromising conditions (described below), including those 
with human immunodeficiency virus (HIV) infection, should receive a 
3-dose series of HPV vaccine at 0, 1–2, and 6 months.
• Pregnant women are not recommended to receive HPV vaccine, 
although there is no evidence that the vaccine poses harm. If a woman 
is found to be pregnant after initiating the HPV vaccination series, delay 
the remaining doses until after the pregnancy. No other intervention 
is needed. Pregnancy testing is not needed before administering HPV 
vaccine.
• Notes: Immunocompromising conditions for which a 3-dose series of 
HPV vaccine is indicated are primary or secondary immunocompromising 
conditions that might reduce cell-mediated or humoral immunity, e.g., 
B-lymphocyte antibody deficiencies, complete or partial T-lymphocyte 
defects, HIV infection, malignant neoplasm, transplantation, autoimmune 
disease, and immunosuppressive therapy.
Footnotes. Reco mended immunization schedule for adults aged 19 years or older, United States, 2017
1. Influe za vaccination
General information
• All persons aged 6 months or older who do not have a 
contrai dication should receive annual influenza vaccination with an 
age-appropriate formulation of inactivated influenza vaccine (IIV) or 
r combinant influenza vaccine (RIV).
• In addition to standard-dose IIV, available options for adults in 
specific age group  include: high-dose or adjuvanted IIV for ad lt
aged 65 years or older, intradermal IIV for adults aged 18 through 64 
years, and RIV for adults aged 18 years or older.
• Notes: Liv  att nuated influenza vaccine (LAIV) should not be used 
during the 2016–2017 influenza season. A list of currently available 
influenza vaccines is available at www.cdc.gov/fl / r tect/vaccine/
vaccines.htm.
Special populations
• Adults with a history of egg allergy who have only hives after 
exposure to egg should receive age-appropriate IIV or RIV.
• Adults with a history of egg allergy other than hives, e.g., 
angioedema, respiratory distress, lightheadedness, or recurrent 
emesis, or who required epinephrine or another emergency medical 
intervention, may receive age-appropriate IIV or RIV. The selected 
vaccine should be administered in an inpatient or outpati nt 
medical setting and under the su ervision of a healthcare provider 
who is able to recognize and manage severe allergic conditions.
• Pr g ant wom n and women who might become pr gnant in the 
upcoming influenza season should receive IIV.
2. Tetanus, diphtheria, nd acellular pertussis vaccinati n
General information
• Adults who have not received tetanus and diphtheria toxoids and 
acellular pertussis vaccine (Tdap) or for whom pertussis vaccination 
statu  is unkn wn should receive 1 dose of Tdap followed by a 
tetanus  diphtheria tox ids (Td) booster every 10 years. Tdap 
should be administered regardless of when a tetanus or diphtheri  
toxoid-containing vaccine was last received.
• Adults with an unk own or incomplet  history of a 3-dose primary 
series with tetanus and diphtheria toxoid-containing vaccines 
should complete the pri ry series that includes 1 dose of Tdap. 
Unvaccinated adults should receive the first 2 doses at least 4 weeks 
apart and the third dose 6–12 months after the second dose.
• Notes: Information on the use of Td or Tdap as tetanus prophylaxis in 
wound management is available at www.cdc.gov/mmwr/preview/
mmwrhtml/rr5517a1.htm.
Special populations
• Pregnant women should receive 1 dose of Tdap during each 
pregnancy, preferably during the early part of gestational weeks 
27–36, regardless of prior history of receiving Tdap.
3. Measles, mumps, and rubella vaccination
General information
• Adults born in 1957 or later without acceptable evidence of 
immunity to measles, mumps, or rubella (defined below) should 
receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless 
they have a medical contraindication to the vaccine, e.g., pregnancy 
or severe immunodeficiency.
• Notes: Acceptable evidence of immunity to measles, mumps, or 
rubella in adults is: born before 1957, documentation of receipt of 
MMR, or laboratory evidence of immunity or disease. Documentation 
of healthcare provider-diagnosed disease without laboratory 
confirmation is not acceptable evidence of immunity.
Special populations
• Pr g nt women who do not have evid nce of immunity to rubella 
should receive 1 dose of MMR upon completion or termination of 
pregnancy and before discharge from the healthcare facility; non-
pregnant women of childbearing age without evidence of rubella 
immunity should receive 1 dose of MMR.
• Adults with primary or acquired immunodeficiency including malignant 
conditions affecting the bone marrow or lymphatic system, systemic 
immunosuppressive therapy, or cellular immunodeficiency should not 
receive MMR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have 
evi ence of measles, mumps, or rubella immunit  should re eive 2 
doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive MMR.
• Adults who work in healthcare facilities should receive 2 doses of MMR 
t least 28 days apart; healthcare personnel born before 1957 who are 
unvaccinated or lack laboratory videnc  of measles, mumps, or rubella 
immunity, or laboratory confirmation of disease should be considered 
for vaccination with 2 doses of MMR at least 28 days apart for me sles or 
mumps, or 1 dose of MMR for rubella.
• Adults who are students in postsec ndary educational institutions or 
plan to travel internationally should receive 2 doses of MMR at least 28 
ays apart.
• Adults who received inactivated (killed) measles vaccine or measles 
vaccine of unknown type during years 1963–1967 should be 
revaccinated with 1 or 2 doses of MMR.
• Adults wh  were vaccinated before 1979 with either inactivated mumps 
vaccine or mumps vaccine of unknow  type who a e at high risk for 
mumps infection, e.g., work in a healthcare facility, should be considered 
for revaccination with 2 doses of MMR at least 28 days apart.
4. Varicella vaccination
Ge eral information
• Adults without evidence of immunity to varicella (defined below) should 
r ceive 2 doses of single antigen varicella v ccine (VAR) 4–8 weeks apart, 
or a second dose if they have received only 1 dose.
• Persons without evidence of immunity for whom VAR should be 
e phasized ar : adults who have close contact with persons at high 
risk for serious complications, e.g., healthcare personnel and household 
contacts of immunocompro ised pe sons; adults who live or wo k in 
an environment in which transmission of varicella zoster virus is likely, 
.g., teachers, childcare workers, a d residents and staff in institutional
settings; adults who live or work in environments in which varicella 
transmission has been reported, e.g., college students, residents and 
staff members of correctional institutions, and military personnel; non-
pregnant women of childbearing age; adolescents and adults living in 
households with children; and international travelers.
• Notes: Evidence of immunity to varicella in adults is: U.S.-born before 
1980 (for pregnant women and healthcare personnel, U.S.-born before 
1980 is not considered evidence of immunity); documentation of 2 
doses of VAR at least 4 weeks apart; history of varicella or herpes zoster 
diagnosis or verification of varicella or herpes zoster disease by a 
healthcare provider; or laboratory evidence of immunity or disease.
Special populations
• Pregnant women should be assessed for evidence of varicella immunity. 
Pregnant women who do not have evidence of immunity should receive 
the first dose of VAR upon completion or termination of pregnancy and 
before discharge from the healthcare facility, and the second dose 4–8 
weeks after the first dose.
• Healthcare institutions should assess and ensure that all healthcare 
personnel have evidence of immunity to varicella.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive VAR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months 
apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 
cells/μl should not receive VAR.
5. Herpes zoster vaccination
General information
• Adults aged 60 years or older should receive 1 dose of herpes zoster 
vaccine (HZV), regardless of whether they had a prior episode of herpes 
zoster.
Special populations
• Adults aged 60 years or older with chronic medical conditions may 
receive HZV unless they have a medical contraindication, e.g., pregnancy 
or severe immunodeficiency.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive HZV.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive HZV.
6. Human papillomavirus vaccination
General information
• Adult females through age 26 years and adult males through age 21 
years who have not received any human papillomavirus (HPV) vaccine 
should receive a 3-dose series of HPV vaccine at 0, 1-2, and 6 months. 
Males aged 22 through 26 years may be vaccinated with a 3-dose series 
of HPV vaccine at 0, 1–2, and 6 months.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received 2 doses at least 5 months apart are considered adequately 
vaccinated and do not need an additional dose of HPV vaccine.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received only 1 dose, or 2 doses less than 5 months apart, are not 
considered adequately vaccinated and should receive 1 additional dose 
of HPV vaccine.
• Notes: HPV vaccination is routinely recommended for children at age 11 
or 12 years. For adults who had initiated but did not complete the HPV 
vaccination series, consider their age at first HPV vaccination (described 
above) and other factors (described below) to determine if they have 
been adequately vaccinated.
Special populations
• Men who have sex with men through age 26 years who have not 
received any HPV vaccine should receive a 3-dose series of HPV vaccine 
at 0, 1-2, and 6 months. 
• Adult females and males through age 26 years with 
immunocompromising conditions (described below), including those 
with human immunodeficiency virus (HIV) infection, should receive a 
3-dose series of HPV vaccine at 0, 1–2, and 6 months.
• Pregnant women are not recommended to receive HPV vaccine, 
although there is no evidence that the vaccine poses harm. If a woman 
is found to be pregnant after initiating the HPV vaccination series, delay 
the remaining doses until after the pregnancy. No other intervention 
is needed. Pregnancy testing is not needed before administering HPV 
vaccine.
• Notes: Immunocompromising conditions for which a 3-dose series of 
HPV vaccine is indicated are primary or secondary immunocompromising 
conditions that might reduce cell-mediated or humoral immunity, e.g., 
B-lymphocyte antibody deficiencies, complete or partial T-lymphocyte 
defects, HIV infection, malignant neoplasm, transplantation, autoimmune 
disease, and immunosuppressive therapy.
Footnotes. Recommended immunization schedule for adults ged 19 y ars or ld r, United States, 2017
1. Influenza vaccination
General information
• All persons aged 6 months or older who do not have a 
contraindication should receive annual influenza vaccination with an 
age-appropriate formulation of inactivated influenza vaccine (IIV) or 
recombinant influenza vaccine (RIV).
• In addition to standard-dose IIV, available options for adults in 
specific age groups include: high-dose or adjuvanted IIV for adults 
aged 65 years or older, intradermal IIV for adults aged 18 through 64 
years, and RIV for adults aged 18 years or older.
• Notes: Live attenuated influenza vaccine (LAIV) should not be used 
during the 2016–2017 influenza season. A list of currently available 
influenza vaccines is available at www.cdc.gov/flu/protect/vaccine/
vaccines.htm.
Special populations
• Adults with a history of egg allergy who have only hives after 
exposure to egg should receive age-appropriate IIV or RIV.
• Adults with a history of egg allergy other than hives, e.g., 
angioedema, respiratory distress, lightheadedness, or recurrent 
emesis, or who required epinephrine or another emergency medical 
intervention, may receive age-appropriate IIV or RIV. The selected 
vaccine should be administered in an inpatient or outpatient 
medical setting and under the supervision of a healthcare provider 
who is able to recognize and manage severe allergic conditions.
• Pregnant women and women who might become pregnant in the 
upcoming influenza season should receive IIV.
2. Tetanus, diphtheria, and acellular pertussis vaccination
General information
• Adults who have not received tetanus and diphtheria toxoids and 
acellular pertussis vaccine (Tdap) or for whom pertussis vaccination 
status is unknown should receive 1 dose of Tdap followed by a 
tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap 
should be administered regardless of when a tetanus or diphtheria 
toxoid-containing vaccine was last received.
• Adults with an unknown or incomplete history of a 3-dose primary 
series with tetanus and diphtheria toxoid-containing vaccines 
should complete the primary series that includes 1 dose of Tdap. 
Unvaccinated adults should receive the first 2 doses at least 4 weeks 
apart and the third dose 6–12 months after the second dose.
• Notes: Information on the use of Td or Tdap as tetanus prophylaxis in 
wound management is available at www.cdc.gov/mmwr/preview/
mmwrhtml/rr5517a1.htm.
Special populations
• Pregnant women should receive 1 dose of Tdap during each 
pregnancy, preferably during the early part of gestational weeks 
27–36, regardless of prior history of receiving Tdap.
3. Measles, mumps, and rubella vaccination
General information
• Adults born in 1957 or later without acceptable evidence of 
immunity to measles, mumps, or rubella (defined below) should 
receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless 
they have a medical contraindication to the vaccine, e.g., pregnancy 
or severe immunodeficiency.
• Notes: Acceptable evidence of immunity to measles, mumps, or 
rubella in adults is: born before 1957, documentation of receipt of 
MMR, or laboratory evidence of immunity or disease. Documentation 
of healthcare provider-diagnosed disease without laboratory 
confirmation is not acceptable evidence of immunity.
Special populations
• Pregnant women who do not have evidence of immunity to rubella 
should receive 1 dose of MMR upon completion or termination of 
pregnancy and before discharge from the healthcare facility; non-
pregnant women of childbearing age without evidence of rubella 
immunity should receive 1 dose of MMR.
• Adults with primary or acquired immunodeficiency including malignant 
conditions affecting the bone marrow or l mphatic system, systemic 
immunosuppressive therapy, or cellular immunodeficiency should not 
receive MMR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have 
evidence of measles, mumps, or rubella immunity should receive 2 
doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive MMR.
• Adults who work in healthcare facilities should receive 2 doses of MMR 
at least 28 days apart; healthcare personnel born before 1957 who are 
unvaccinated or lack laboratory evidence of measles, mumps, or rubella 
immunity, or laboratory confirmation of disease should be considere  
for vaccination with 2 doses of MMR at least 28 days apart for measles or 
mumps, or 1 dose of MMR for rubella.
• Adults who are students in postsecon ary educational institutions or 
plan to travel internationally should receive 2 doses of MMR at least 28 
days apart.
• Adults who rec ived inactivated (killed) measles vaccine or measles 
vaccine of unknown type during years 1963–1967 should be 
revaccinated with 1 or 2 doses of MMR.
• Adults who were vaccinated before 1979 with either inactivated mumps 
vaccine or mumps vaccine of unknown type who are at high risk for 
mumps infection, e.g., work in a healthcare facility, should be considered 
for revaccination with 2 doses of MMR at least 28 days apart.
4. Varicella vaccination
General information
• Adults without evidence of immunity to varicella (defined below) should 
receive 2 doses of single-antigen varicella vaccine (VAR) 4–8 weeks apart, 
or a second dose if they have received only 1 dose.
• Persons without evidence of immunity for whom VAR should be 
emphasized are: adults who have close contact with persons at high 
risk for serious complications, e.g., healthcare personnel and household 
contacts of immunocompromised persons; adults who live or work in 
an environment in which transmission of varicella zoster virus is likely, 
e.g., teachers, childcare workers, and residents and staff in institutional 
settings; adults who live or work in environments in which varicella 
transmission has been reported, e.g., college students, residents and 
staff members of correctional institutions, and military personnel; non-
pregnant women of childbearing age; adolescents and adults living in 
households with children; and international travelers.
• Notes: Evidence of immunity to varicella in adults is: U.S.-born before 
1980 (for pregnant women and healthcare personnel, U.S.-born before 
1980 is not considered evidence of immunity); documentation of 2 
doses of VAR at least 4 weeks apart; history of varicella or herpes zoster 
diagnosis or verification of varicella or herpes zoster disease by a 
healthcare provider; or laboratory evidence of immunity or disease.
Special populations
• Pregnant women should be assessed for evidence of varicella immunity. 
Pregnant women who do not have evidence of immunity should receive 
the first dose of VAR upon completion or termination of pregnancy and 
before discharge from the healthcare facility, and the second dose 4–8 
weeks after the first dose.
• Healthcare institutions should assess and ensure that all healthcare 
personnel have evidence of immunity to varicella.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive VAR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months 
apart. Adults with HIV infection and CD4+ T-lymphocyte count <200 
cells/μl should not receive VAR.
5. Herpes zoster vaccination
General information
• Adults aged 60 years or older should receive 1 dose of herpes zoster 
vaccine (HZV), regardless of whether they had a prior episode of herpes 
zoster.
Special populations
• Adults aged 60 years or older with chronic medical conditi ns may 
receive HZV unless they have a medical contraindication, e.g., pregnancy 
or severe immunodeficiency.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immunosuppressive therapy, should not receive HZV.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive HZV.
6. Human papillomavirus vaccination
General information
• Adult females through age 26 years and adult males through age 21 
years who have not received any human papillomavirus (HPV) vaccine 
should receive a 3-dose series of HPV vaccine at 0, 1-2, and 6 months. 
Males aged 22 through 26 years may be vaccinated with a 3-dose series 
of HPV vaccine at 0, 1–2, and 6 months.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received 2 doses at least 5 months apart are considered adequately 
vaccinated and do not need an additional dose of HPV vaccine.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received only 1 dose, or 2 doses less than 5 months apart, are not 
considered adequately vaccinated and should receive 1 additional dose 
of HPV vaccine.
• Notes: HPV vaccination is routinely recommended for children at age 11 
or 12 years. For adults who had initiated but did not complete the HPV 
vaccination series, consider their age at first HPV vaccination (described 
above) and other factors (described below) to determine if they have 
been adequately vaccinated.
Special populations
• Men who have sex with men through age 26 years who have not 
received any HPV vaccine should receive a 3-dose series of HPV vaccine 
at 0, 1-2, and 6 months. 
• Adult females and males through age 26 years with 
immunocompromising conditions (described below), including those 
with human immunodeficiency virus (HIV) infection, should receive a 
3-dose series of HPV vaccine at 0, 1–2, and 6 months.
• Pregnant women are not recommended to receive HPV vaccine, 
although there is no evidence that the vaccine poses harm. If a woman 
is found to be pregnant after initiating the HPV vaccination series, delay 
the remaining doses until after the pregnancy. No other intervention 
is needed. Pregnancy testing is not needed before administering HPV 
vaccine.
• Notes: Immunocompromising conditions for which a 3-dose series of 
HPV vaccine is indicated are primary or secondary immunocompromising 
conditions that might reduce cell-mediated or humoral immunity, e.g., 
B-lymphocyte antibody deficiencies, complete or partial T-lymphocyte 
defects, HIV infection, malignant neoplasm, transplantation, autoimmune 
disease, and immunosuppressive therapy.
Footnotes. Recommended immunization schedule for adults aged 19 years or older, United States, 2017
1. Influenza vaccination
General information
• All persons aged 6 months or older who do not have a 
contraindication should receive annual influenza vaccination with an 
age-appropriate formulation of inactivated influenza vaccine (IIV) or 
recombinant influenza vaccine (RIV).
• In addition to standard-dose IIV, available options for adults in 
specific age groups include: high-dose or adjuvanted IIV for adults 
aged 65 years or older, intradermal IIV for adults aged 18 through 64 
years, and RIV for adults aged 18 years or older.
• Notes: Live attenuated influenza vaccine (LAIV) should not be used 
during the 2016–2017 influenza season. A list of currently available 
influenza vaccines is available at www.cdc.gov/flu/protect/vaccine/
vaccines.htm.
Special populations
• Adults with a history of egg allergy who have only hives after 
exposure to egg should receive age-appropriate IIV or RIV.
• Adults with a history of egg allergy other than hives, e.g., 
angioedema, respiratory distress, lightheadedness, or recurrent 
emesis, or who required epinephrine or another emergency medical 
intervention, may receive age-appropriate IIV or RIV. The selected 
vaccine should be administered in an inpatient or outpatient 
medical setting and under the supervision of a healthcare provider 
who is able to recognize and manage severe allergic conditions.
• Pregnant women and women who might become pregnant in the 
upcoming influenza season should receive IIV.
2. Tetanus, diphtheria, and acellular pertussis vaccination
General information
• Adults who have not received tetanus and diphtheria toxoids and 
acellular pertussis vaccine (Tdap) or for whom pertussis vaccination 
status is unknown should receive 1 dose of Tdap followed by a 
tetanus and diphtheria toxoids (Td) booster every 10 years. Tdap 
should be administered regardless of when a tetanus or diphtheria 
toxoid-containing vaccine was last received.
• Adults with an unknown or incomplete history of a 3-dose primary 
series with tetanus and diphtheria toxoid-containing vaccines 
should complete the primary series that includes 1 dose of Tdap. 
Unvaccinated adults should receive the first 2 doses at least 4 weeks 
apart and the third dose 6–12 months after the second dose.
• Notes: Information on the use of Td or Tdap as tetanus prophylaxis in 
wound management is available at www.cdc.gov/mmwr/preview/
mmwrhtml/rr5517a1.htm.
Special populations
• Pregnant women should receive 1 dose of Tdap during each 
pregnancy, preferably during the early part of gestational weeks 
27–36, regardless of prior history of receiving Tdap.
3. Measles, mumps, and rubella vaccination
General information
• Adults born in 1957 or later without acceptable evidence of 
immunity to measles, mumps, or rubella (defined below) should 
receive 1 dose of measles, mumps, and rubella vaccine (MMR) unless 
they have a medical contraindication to the vaccine, e.g., pregnancy 
or severe immunodeficiency.
• Notes: Acceptable evidence of immunity to measles, mumps, or 
rubella in adults is: born before 1957, documentation of receipt of 
MMR, or laboratory evidence of immunity or disease. Documentation 
of healthcare provider-diagnosed disease without laboratory 
confirmation is not acceptable evidence of immu ity.
Special populations
• Pregnant women who do not have evidence of immunity to rubella 
should receive 1 dose of MMR upon completion or termination of 
pregnancy and before discharge from the healthcare facility; non-
pregnant women of childbearing age without evidence of rubella 
immunity should receive 1 dose of MMR.
• Adults with primary or acquired immunodeficiency including malignant 
conditi ns affecting the bone marrow r lymphatic system, systemic 
immunosup ressive therapy, or c llular immuno eficiency should not 
receive MMR.
• Adults with human immunod ficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl for at least 6 months who do not have 
evidence of measles, mumps, or rubella immunity shoul  receiv  2 
doses of MMR at least 28 days apart. Adults with HIV infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive MMR.
• Adults who work in healthcare facilities hould receive 2 doses of MMR 
at least 28 days apart; healthcare personnel born before 1957 who are 
unvaccinated or lack laboratory evidence of measles, mumps, or rubella 
immunity, or laboratory confirmation of disease should be considered 
for vaccinati n with 2 doses of MMR at least 28 days apart for measles or 
mu ps, or 1 dose of MMR for rubella.
• Adults who are stud nts in postsecondary ducational institutions or 
plan to travel int rnationally sh uld receive 2 doses of MMR at least 28 
days apart.
• Adults who received inactivated (killed) measles va cine or measles 
vaccine of unknown type during years 1963–1967 should be 
revaccinated with 1 or 2 doses of MMR.
• Adults who were vaccinated before 1979 with either inactivated mumps 
vaccine or mumps vaccine of unknown type who are at high risk for 
mum s infection, e.g., work in a healthcare facility, should be considered 
for revaccination with 2 doses of MMR at least 28 days apart.
4. Varicell  vaccination
General information
• Adults without evidence of immunity to varicella (defined below) should 
receive 2 doses of single-antigen varicella vaccine (VAR) 4–8 weeks apart, 
or a second dose if they have received only 1 dose.
• Persons without evidence of immunity for whom VAR should be 
emphasized are: adults who have close contact with persons at high 
risk for serious complications, e.g., healthcare personnel and household 
contacts of immunocompromised persons; adults who live or work in 
an environment in which transmission of varicella zoster virus is likely, 
e.g., teachers, childcare workers, and r sidents and staff in institutional 
settings; adults who live or work in environments in whic  v ricella 
transmission has been reported, e.g., colle e students, residents and 
staff members of correctional institutions, and military personnel; non-
pregnant women of childbearing age; adolescents and adults living in 
households with children; and international travelers.
• Notes: Evidence of immunity to varicella in adults is: U.S.-born before 
1980 (for pregnant women and healthcare personnel, U.S.-born before 
1980 is not considered evidence of immunity); documentation of 2 
doses of VAR at least 4 weeks apart; history of varicella or herpes zoster 
diagnosis or verification of varicella or herpes zoster disease by a 
healt care provider; or laboratory evidenc  of immunity r diseas .
Special populations
• Pregnant women should be assessed for evidence of varicella immunity. 
Pregnant women who do not have evidence of immunity should receive 
the first do e of VAR upon completion or termination of pregnancy and 
before discharge from the healthcare facility, and the second dose 4–8 
weeks after th  first dose.
• Healthcare institutions should assess and sure that all healthcare 
personnel have evidence of i to varicella
• Adults with malignant condition , includ ng those that affect 
the b e marrow or lymphatic syst m or who receive systemic 
immunosuppressive therapy, should not receive VAR.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count ≥200 cells/μl may receive 2 doses of VAR 3 months 
apart. Adults with HIV infection and CD4+ T-lymphocyte c unt <200 
cells/μl should not receive VAR.
5. Herpes zoster vaccination
General information
• Adults aged 60 y ars or older should receive 1 dose of herpes zoster 
vaccine (HZV), regardless of whether they had a prior episode of herpes 
zoster.
Speci l populations
• Adults aged 60 years or older with chronic medical conditions may 
receive HZV unless they have a medical contraindication, e.g., pregnancy 
or severe immunodeficiency.
• Adults with malignant conditions, including those that affect 
the bone marrow or lymphatic system or who receive systemic 
immu suppressive therapy, should not receive HZV.
• Adults with human immunodeficiency virus (HIV) infection and CD4+ 
T-lymphocyte count <200 cells/μl should not receive HZV.
6. Human papillomavirus vaccination
General inform tion
• Adult females through age 26 years and adult males through age 21 
years who have not received any human papillomavirus (HPV) vaccine 
should receive a 3-dose series of HPV vaccine at 0, 1-2, and 6 months. 
Males aged 22 through 26 years may be vaccinated with a 3-dose series 
of HPV vaccine at 0, 1–2, and 6 months.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received 2 doses at least 5 months apart are considered adequately 
vaccinated and do not need an additional dose of HPV vaccine.
• Adult females through age 26 years and adult males through age 
21 years (and males aged 22 through 26 years who may receive HPV 
vaccination) who initiated the HPV vaccination series before age 15 years 
and received only 1 dose, or 2 doses less than 5 months apart, are not 
onsidered adequately vaccinated and should receive 1 additional dose 
of HPV vaccine.
• Notes: HPV vaccination is routinely recommended for children at age 11 
or 12 years. For adults who had initiated but did not complete the HPV 
vaccination series, consider their age at first HPV vaccination (described 
above) and other factors (described below) to determine if they have 
been adequately vaccinated.
Special populations
• Men who have sex with men through age 26 years who have not 
received any HPV vaccine should receive a 3-dose series of HPV vaccine 
at 0, 1-2, and 6 months.
• Adult fem les and males throug  g  26 years with 
immunocompromising conditions (described below), including those 
with human immunodeficiency virus (HIV) inf cti n, should receive a 
3-dose s ries of HPV vaccine t 0, 1–2, and 6 months.
• Pregnant women re not recommended to receive HPV vaccine, 
although there is no evidence that the vaccine poses harm. If a woman 
is found to be pregnant after initiating the HPV vaccination series, delay 
the remaining doses until after the pregnancy. No other intervention 
is needed. Pregnancy testing is not needed before administering HPV 
vaccine.
• Not s: Immunocompromising conditions for which a 3-dose series of 
HPV vaccine is indicate  re primary or econdary immunocompromising 
conditions that might reduce cell-mediat d or humoral immunity, e.g., 
B-lymph cyte antibo y deficiencies, compl te or partialT-lymphocyte 
defects, HIV infection, malignant neoplasm, transplantation, autoimmune 
disease, and immunosuppressive therapy.
7. Pneumococcal vaccination
General information
• Adults who are immunocompetent and aged 65 years or older should 
receive 13-valent pneumococcal conjugate vaccine (PCV13) followed by 
23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year 
after PCV13.
• Not s: Adults are recommended to receive 1 d se of PCV13 and 1, 2, 
or 3 doses of PPSV23 dep nding on indic tion. When both PCV13 and 
PPSV23 are indicated, PCV13 should be administered first; PCV13 and 
PPSV23 should not be administered during the same visit. If PPSV23 has 
previously been administered, PCV13 should be administered at least 1 
year after PPSV23. When two or more doses of PPSV23 are indicated, the 
interval between PPSV23 doses should be at least 5 years. Supplemental 
information on pneumococcal vaccine timing for adults aged 65 years 
or older and adults aged 19 years or older at high risk f r neumococcal 
disease (described below) is available at www.cdc.gov/vaccines/vpd-vac/
pneumo/downloads/adult-vax-clinician-aid.pdf. No additional doses of 
PPSV23 are indicated for adults who received PPSV23 at age 65 years 
or older. When indicated, PCV13 and PPSV23 should be administered 
to adults whose pneumococcal vaccination history is incomplete or 
unknown.
Special populations
• Adults aged 19 through 64 years with chronic heart disease including 
congestive heart failure and cardiomyopathies (excluding hypertension); 
chronic lung disease including chronic obstructive lung disease, 
emphysema, and asthma; chronic liver disease including cirrhosis; 
alcoholism; or diabetes mellitus; or who smoke cigarettes should receive 
PPSV23. At age 65 years or older, they should receive PCV13 and another 
dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the 
most recent dose of PPSV23.
• Adults aged 19 years or older with immunoc mpromising conditions or 
anatomical r function l asplenia (described below) should receive PCV13 
and  dose f PPSV23 at least 8 weeks after PCV13, followed by a second 
dose of PPSV23 at least 5 years after the first dose of PPSV23. If the most 
rece t dose of PPSV23 was admin stered b fore age 65 years, at age 65 
y ars or older, administer anoth r dose of PPSV23 t least 8 weeks after 
PCV13 and at l ast 5 years after the most nt dose of PPSV23.
• Adults aged 19 years or older with cerebrospinal fluid leak or cochlear 
implant should receive PCV13 followed by PPSV23 at least 8 weeks after 
PCV13. If the most recent dose of PPSV23 was ad inist red before age 
65 years, at age 65 y ars or older, administer nother dose of PPSV23 at 
least 8 weeks after PCV13 an  at least 5 years after the most recent dose 
of PPSV23.
• Notes: Immunocompromising conditions that are indications for 
pneumococcal vaccination are congenital or acquired immunodeficiency 
including B- or T-lymphocyte deficiency, complement deficiencies, 
and phagocytic disorders excluding chronic granulomatous disease; 
human immunodeficiency virus (HIV) infection; chronic renal failure 
and nephrotic syndrome; leukemia, lymphoma, Hodgkin disease, 
generalized malignancy, and multiple myeloma; solid organ transplant; 
and iatrogenic immunosuppression including long-term systemic 
corticosteroid and radiation therapy. Anatomical or functional asplenia 
that are indications for pneumococcal vaccination are sickle cell disease 
and oth r hemoglobinopathies, congenital or acquired spleni , splenic 
dysfunction, and splenectomy. Pneumococcal vacci e  should be given 
at least 2 we ks before immunosuppressive therapy or an elective 
splenectomy, and as soon as possible to adults who ar  diagnosed with 
HIV infection.
8. Hepatitis A vaccination
General information
• Adults who seek protection from hepatitis A virus infection may receive 
a 2-dose series of single antigen hepa itis A vaccine (HepA) at eith r 0 
and 6–12 onths (Havrix) or 0 and 6–18 months (Vaqta). Adults may 
also receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) as a 3-dose series at 0, 1, and 6 months. Acknowledgment of a 
specific risk factor by those who seek protection is not needed.
Special populations
• Adults with any of the following indications should receive a HepA 
series: have chronic liver disease, receive clotting factor concentrates, 
men who have sex with men, use injection or non-injection drugs, 
or work with hepatitis A virus-infected primates or in a hepatitis A 
research laboratory setting.
• Adults who travel in countries with high or intermediate levels of 
endemic hepatitis A infection or anticipate close personal contact 
with an international adoptee, e.g., reside in the same household or 
regularly babysit, from a country with high or intermediate level of 
endemic hepatitis A infection within the first 60 days of arrival in the 
United States should receive a H pA seri s.
9. Hepatitis B vaccination
General information
• Adults who seek protection from hepatitis B virus infection may 
receive a 3-dose series of single-antigen hepatitis B vaccine (HepB) 
(Engerix-B, Recombivax HB) at 0, 1, a d 6 months. Adults may also 
receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) at 0, 1, and 6 months. Acknowledgment of a specific risk 
factor by those who seek protection is n t nee ed.
Special populations
• Adults at risk for hepatitis B virus infection by sexual exposure should 
receive a HepB series, including sex partners of hepatitis B surface 
antigen (HBsAg)-positive persons, sexually active persons who 
are not in a mutually monogamous relationship, persons seeking 
evaluation or treatment for a sexually transmitted infection, and men 
who have sex with men (MSM).
• Adults at risk for hepatitis B virus infection by percutaneous or 
mucosal exposure to blood should receive a HepB series, including 
adults who are recent or current users of injection drugs, household 
contacts of HBsAg-positive persons, residents and staff of facilities 
for developmentally disabled persons, incarcerated, healthcare 
and public safety workers at risk for exposure to blood or blood-
contaminated body fluids, younger than age 60 years with diabetes 
mellitus, and age 60 years or older with diabetes mellitus at the 
discretion of the treating clinician.
• Adults with chronic liver disease including, but not limited to, 
hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver 
disease, autoimmune hepatitis, and an alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) level greater than twice 
the upper limit of normal should receive a HepB series.
• Adults with end-stage renal disease including those on pre-dialysis 
care, hemodialysis, peritoneal dialysis, and home dialysis should 
receive a HepB series. Adults on hemodialysis should receive a 
3-dose series of 40 µg Recombivax HB at 0, 1, and 6 months or a 
4-dose series of 40 µg Engerix-B at 0, 1, 2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection should 
receive a HepB series.
• Pregnant women who are at risk for hepatitis B virus infection 
during pregnancy, e.g., having more than one sex partner during 
the previous six months, been evaluated or treated for a sexually 
transmitted infection, recent or current injection drug use, or had an 
HBsAg-positive sex partner, should receive a HepB series.
• International travelers to regions with high or intermediate levels of 
endemic hepatitis B virus infection should receive a HepB series.
• Adults in the following settings are assumed to be at risk for 
hepatitis B virus infection and should receive a HepB series: sexually 
transmitted disease treatment facilities, HIV testing and treatment 
facilities, facilities providing drug-abuse treatment and prevention 
services, healthcare settings targeting services to persons who 
inject drugs, correctional facilities, healthcare settings targeting 
services to MSM, hemodialysis facilities and end-stage renal disease 
programs, and institutions and nonresidential day care facilities for 
developmentally disabled persons.
10. Meningococcal vaccination
Special populations
• Adults with anatomical or functional asplenia or persistent complement 
component deficiencies should rec ive a 2-dose primary series of 
serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) 
at least 2 months apart and revaccinate every 5 years. They should also 
receive a series of erogroup B meningococcal vaccin  (MenB) with either 
a 2-dose series of MenB-4C (Bexsero) at least 1 month apart or a 3-dose 
series of MenB-FHbp (Trumenba) at 0, 1–2, and 6 months.
• Adults with human im nodeficien y virus (HIV) infection who have 
not been previously vaccinated should receive a 2-dose primary series of 
MenACWY at least 2 months apart and revaccinate every 5 years. Those 
who previously received 1 dose of MenACWY should receive a second 
dose at least 2 months after the first dose. Adults with HIV infection are 
not routinely recommended to receive MenB because meningococcal 
disease in this population is c used primarily by serogroups C, W, and Y.
• Microbiologists who are routinely exposed to isolates of Neisseria 
meningitidis should receive 1 dose of MenACWY and revaccinate every 5 
years if th  risk for infection remains, a d either a 2-dos  series of MenB-
4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 
6 months.
• Adults at risk because of a meningococcal disease outbreak should 
receive 1 dose of MenACWY if the outbreak is attributable to serogroup 
A, C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or 
a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months if the outbreak is 
attributable to serogroup B.
• Adults who travel to or live in countries with hyperendemic or epidemic 
meningococcal disease should receive 1 dose of MenACWY and 
revaccinate every 5 years if the risk for infection remains. MenB is not 
routinely indicated because meningococcal disease in these countries is 
generally not caused by serogroup B.
• Military recruits should receive 1 dose of MenACWY and revaccinate 
every 5 years if the increased risk for infection remains.
• First-year college students aged 21 years or younger who live in 
residence halls should receive 1 dose of MenACWY if they have not 
received MenACWY at age 16 years or older.
• Young adults aged 16 through 23 years (preferred age range is 16 
through 18 years) who are healthy and not at increased risk for serogroup 
B meningococcal disease (described above) may receive either a 2-dose 
series of MenB-4C at least 1 month apart or a 2-dose series of MenB-
FHbp at 0 and 6 months for short-term protection against most strains of 
serogroup B meningococcal disease. 
• For adults aged 56 years or older who have not previously received 
serogroups A, C, W, and Y meningococcal vaccine and need only 1 
dose, meningococcal polysaccharide serogroups A, C, W, and Y vaccine 
(MPSV4) is preferred. For adults who previously received MenACWY 
or anticipate receiving multiple doses of serogroups A, C, W, and Y 
meningococcal vaccine, MenACWY is preferred. 
• Notes: MenB-4C and MenB-FHbp are not interchangeable, i.e., the same 
vaccine should be used for all doses to complete the series. There is no 
recommendation for MenB revaccination at this time. MenB may be 
administered at the same time as MenACWY but at a different anatomic 
site, if feasible.
11.  Haemophilus influenzae type b vaccination
Special populations
• Adults who have anatomical or functional asplenia or sickle cell disease, 
or are undergoing elective splenectomy should receive 1 dose of 
Haemophilus influenzae type b conjugate vaccine (Hib) if they have not 
previously received Hib. Hib should be administered at least 14 days 
before splenectomy.
• Adults with a hematopoietic stem cell transplant (HSCT) should receive 
3 doses of Hib in at least 4 week intervals 6–12 months after transplant 
regardless of their Hib history.
• Notes: Hib is not routinely recommended for adults with human 
immunodeficiency virus infection because their risk for Haemophilus 
influenzae type b infection is low.
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7. Pneumococcal vaccination
General information
• A ults wh  a  immun compet n  and aged 65 years or older should 
rec ive 13-valent p eumococcal conjugate vaccine (PCV13) followed by 
23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year 
after PCV13.
• Notes: Adults are recommended to receive 1 dose of PCV13 and 1, 2, 
or 3 doses of PPSV23 depending o  indication. W en both PCV13 and 
PPSV23 are indicated, PCV13 should be administered first; PCV13 and 
PPSV23 should not be administered during the same visit. If PPSV23 has 
previously been administered, PCV13 should be administer d at least 1 
year after PPSV23. When two or more doses of PPSV23 are indicated, the 
interval between PPSV23 dose should be at least 5 years. Supplemental 
infor ation on pneumococcal vaccine timing for adults aged 65 years 
or older and adults aged 19 years or older at high risk for pneumococcal 
di ease (described below) is available at www.cdc.gov/vaccines/vpd-vac/
pne mo/downl ads/a ult-vax-clinician-aid.pdf. N  additional doses of 
PPSV23 are i dicated for adults who r ceived PPSV23 t ag  65 y ars
r lder. When indicat d, PCV13 and PPSV23 sh uld be administered 
to adults whose pneumococcal vaccination history is incomplete or 
unknown.
Special populations
• Adults aged 19 through 64 years with chronic heart disease including 
congestive heart failure and cardiomyopathies (excluding hypertension); 
chronic lung disease including chronic obstructive lung isease, 
emphysema, and asthma; chronic liver disease including cirrhosis; 
alcoholism; or diabetes mellitus; or who smoke cigarettes should receive 
PPSV23. At age 65 y ars or older, they should re eive PCV13 and another 
dose of PPSV23 at least 1 year after PCV13 and at least 5 y ars after the 
most recent dose of PPSV23.
• Adults aged 19 years or older with immuno mpromising conditions or 
anatomical r function l asplenia (described below) should receive PCV13 
and  dose f PPSV23 at least 8 weeks after PCV13, followed by a second 
dose of PPSV23 at least 5 years after the first dose of PPSV23. If the most 
rece t dose of PPSV23 was administered b fore age 65 years, at age 65 
y ars or older, administer anoth r dose of PPSV23 t least 8 weeks after 
PCV13 and at l ast 5 years after t e ost r nt ose of PPSV23.
• Adults aged 19 years or older with cerebrospinal fluid leak or cochlear 
implant should receive PCV13 followed by PPSV23 at least 8 weeks after 
PCV13. If the most recent dose of PPSV23 was ad inistered before age 
65 years, at age 65 years or older, administer another dose of PPSV23 at 
least 8 weeks after PCV13 an  at least 5 years after the most recent dose 
of PPSV23.
• Notes: Immunocompromising conditio s that are indic tions for 
pneumococcal vaccination are congenital or acquired immunodeficiency 
including B- or T-ly phocyte deficie cy, complement deficiencies, 
and phagocytic disorders excluding chronic granulomatous disease; 
human i u deficiency virus (HIV) infection; chronic renal failure 
and n phrotic syndrome; leukemia, lymphoma, Hodgkin disease, 
ge eralized mali na cy, and multiple myeloma; solid organ transplant; 
and iatrogenic immunosuppre sion including long-term syst mic 
corticosteroid and radiation ther py. Anatomical or functional asplenia 
that are indications for pneumococcal vaccination are sickle cell disease 
nd oth r hemoglobinopathies, congenital or acquired spleni , splenic 
dysfunction, and splenectomy. Pneumococcal vacci e  should be given 
at least 2 we ks before immunosuppressive therapy or an elective 
splenectomy, and as soon as possible to adults who ar  diagnosed with 
HIV infection.
8. Hepatitis A vaccination
General information
• Adults who seek protection from epatitis A virus inf ction may receiv  
 2-dose series of single antigen hepa itis A vaccine (HepA) at eith r 0 
and 6–12 onths (Havrix) r 0 and 6–18 months (Vaqta). Adults may 
also rec i e a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) as a 3-dose series at 0, 1, and 6 months. Acknowledgment of a 
specific risk factor by those who seek protection is not needed.
Special populations
• Adults with any of the following indications should receive a HepA 
series: have chronic liver disease, receive clotting factor concentrates, 
men who have sex with men, use injection or non-injection drugs, 
or w rk with hepatitis A virus-infected primates or in a hepatitis A 
research laboratory setting.
• Adults who travel in countries with high or intermediate levels of 
endemic hepatitis A infection or anticipate close personal contact 
with an international adoptee, e.g., reside in the same household or 
regularly babysit, from a country with high or intermediate level of 
endemic hepatitis A infection within the first 60 days of arrival in the 
Unit d States should receive a HepA series.
9. Hepatitis B vaccination
General informat on
• Adults who seek protection from hepatitis B virus infection may 
receive a 3-dose series of single-antigen hepatitis B vaccine (HepB) 
(Engerix-B, Recombivax HB) at 0, 1, and 6 months. Adults may also 
receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) at 0, 1, and 6 months. Acknowledgment of a specific risk 
factor by those who seek protection is not needed.
Specia  populati ns
• Adults at risk for hepatitis B virus infection by sexual exposure should 
receive a HepB series, including sex partners of hepatitis B surface 
antigen (HBsAg)-positive persons, sexually active persons who 
are not in a mutually monogamous relationship, persons seeking 
evaluation or treatment for a sexually transmitted infection, and men 
who have sex with men (MSM).
• Adults at risk for hepatitis B virus infection by percutaneous or 
mucosal exposure to blood should receive a HepB series, including 
adults who are recent or current users of injection drugs, household 
contacts of HBsAg-positive persons, residents and staff of facilities 
for developmentally disabled persons, incarcerated, healthcare 
and public safety workers at risk for exposure to blood or blood-
contaminated body fluids, younger than age 60 years with diabetes 
mellitus, and age 60 years or older with diabetes mellitus at the 
discretion of the treating clinician.
• Adults with chronic liver disease including, but not limited to, 
hepatitis C virus infect on, cirrhosis, fatty liver disease, alcoholic liver 
disease, autoimmune hepatitis, and an alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) level greater than twice 
t e upper limit of normal should receive a HepB series.
• Adults with end-stage renal disease including those on pre-dialysis 
care, hemodialysis, peritoneal dialysis, and home dialysis should 
receive a HepB series. Adults on hemodialysis sh uld receive a 
3-dose series of 40 µg Recombivax HB at 0, 1, and 6 months or a 
4-dose series of 40 µg Engerix-B at 0, 1, 2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection should 
receive a HepB series.
• Pregnant women who are at risk for hepatitis B virus infection 
during pregnancy, e.g., h ving ore than one sex partner during 
the previous six onths, been valuated or treated for a sexually 
transmitted infection, recent or current injection drug use, or had an 
HBsA -positiv  sex partner, should receive a HepB s ries.
• Internatio al travelers to regions with igh or intermediate levels of 
endemic hepatitis B virus infection should receive a HepB series.
• Adults in the following settings are assumed to be at risk for 
hepatitis B virus infection and should receiv  a HepB series: sexually 
tra smitted disease treatment f cilities, HIV testing and treatment 
f cilities, facilities provi ing drug-abuse treatment and prevention 
s rvices, healthcare settings targeting services to persons who 
i j ct drugs, correctional facilities, healthcare settings targeting 
services to MSM, h modialysis facilities and end-stage renal disease 
rogr ms, and institutions and nonresidential day care facilities for 
developmentally disabled persons.
10. Meningococcal vaccination
Special populations
• Adults with anatomical or functional asplenia or persistent complement 
component deficiencies should receive a 2-dose primary series of 
serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) 
at least 2 months apart and revaccinate every 5 years. They should also 
receive a series of serogroup B meningococcal vaccine (MenB) with either 
a 2-dose series of MenB-4C (Bexsero) at least 1 month apart or a 3-dose 
series of MenB-FHbp (Trumenba) at 0, 1–2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection who have 
not been previously vaccinated should receive a 2-dose primary series of 
MenACWY at least 2 months apart and revaccinate very 5 ye rs. Th se 
who previously received 1 dose of MenACWY should receive a second 
dose at least 2 months after the first dose. Adults with HIV infection are 
not routinely recommended to receive MenB because meningococcal 
disease in this population is caused primarily by serogroups C, W, and Y.
• Microbiologists who are routinely exposed to isolates of Neisseria 
meningitidis should receive 1 dose of MenACWY and revaccinate every 5 
years if the risk for infection remains, and either a 2-dose series of MenB-
4C at least 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 
6 months.
• Adults at risk because of a meningococcal disease outbreak should 
receive 1 dose of MenACWY if the outbreak is attributable to serogroup 
A, C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or 
a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months if the outbreak is 
attributable to serogroup B.
• Adults who travel to or live in countries with hyperendemic or epidemic 
meningococcal disease should receive 1 dose f MenACWY and 
revaccinate every 5 years if the risk for infection remains. MenB is not 
routinely indicated because meningococcal disease in these countries is 
generally not caused by serogroup B.
• Military recruits should receive 1 dose of MenACWY and revaccinate 
every 5 years if the increased risk for infection remains.
• First-year college students aged 21 years or younger who live in 
residence halls should receive 1 dose of MenACWY if they have not 
received MenACWY at age 16 years or older.
• Young adults aged 16 through 23 years (preferred age range is 16 
through 18 years) who are healthy and not at increased risk for serogroup 
B meningococcal disease (described above) may receive either a 2-dose 
series of MenB-4C at least 1 month apart or a 2-dose series of MenB-
FHbp at 0 and 6 months for short-term protection against most strains of 
serogroup B meningococcal disease. 
• For adults aged 56 years or older who have not previously received 
serogroups A, C, W, and Y meningococcal vaccine and need only 1 
dose, meningococcal polysaccharide serogroups A, C, W, and Y vaccine 
(MPSV4) is preferred. For adults who previously received MenACWY 
or anticipate receiving multiple doses of serogroups A, C, W, and Y 
meningococcal vaccine, MenACWY is preferred. 
• Notes: MenB-4C and MenB-FHbp are not interchangeable, i.e., the same 
vaccine should be used for all doses to complete the series. There is no 
recommendation for MenB revaccination at this time. MenB may be 
administered at the same time as MenACWY but at a different anatomic 
site, if feasible.
11.  Haemophilus influenzae type b vaccination
Special populations
• Adults who have anatomical or functional asplenia or sickle cell disease, 
or are undergoing elective splenectomy should receive 1 dose of 
Haemophilus influenzae type b conjugate vaccine (Hib) if they have not 
previously received Hib. Hib should be administered at least 14 days 
before splenectomy.
• Adults with a hematopoietic stem cell transplant (HSCT) should receive 
3 doses of Hib in at least 4 week intervals 6–12 months after transplant 
regardless of their Hib history.
• Notes: Hib is not routinely recommended for adults with human 
immunodeficiency virus infection because their risk for Haemophilus 
influenzae type b infection is low.
7. Pneumococcal vaccination
General information
• Adults who are im unocompetent and ag d 65 years or older should 
receive 13-valent pneumococcal conjugate vaccine (PCV13) followed by 
23-valent pneumococcal polysaccharide vaccine (PPSV23) at least 1 year 
after PCV13.
• Notes: Adults are recommended to receive 1 dose of PCV13 and 1, 2, 
or 3 doses of PPSV23 depending on indication. When both PCV13 and 
PPSV23 are indicated, PCV13 should be administered first; PCV13 and 
PPSV23 should not be administered during the same visit. If PPSV23 has 
previously been administered, PCV13 should be administered at least 1 
year after PPSV23. When two or more doses of PPSV23 are indicated, the 
interval between PPSV23 doses should be at least 5 years. Supplemental 
information on pneumococcal vaccine timing f r ad lts aged 65 y ars 
or older and adults aged 19 years or older at high risk for pneumococcal 
disease (described below) is available at www.cdc.gov/vaccines/vpd-vac/
pneumo/downloads/a ult-vax-clinician-aid.pdf. No additional doses of 
PPSV23 are indicated for adults who received PPSV23 at age 65 years 
or older. When indicated, PCV13 and PPSV23 should be administered 
to adults whose pneumococcal vaccination history is incomplete or 
unknown.
Special populations
• Adults aged 19 through 64 ears with chronic heart disease including 
congestive heart failure and cardiomyopathies (excluding hypertension); 
chronic lung disease including chronic obstructive lung disease, 
emphysema, and asthma; chroni  liver diseas  inclu ing cirrhosis; 
alcoholism; or diabetes mellitus; or who smoke cigarettes should receive 
PPSV23. At age 65 years or older, they should receive PCV13 and another 
dose of PPSV23 at least 1 year after PCV13 and at least 5 years after the 
most recent dose of PPSV23.
• Adults aged 19 years or older with immunocompromising conditions or 
anatomical or functional asplenia (described below) should receive PCV13 
and a dose of PPSV23 at least 8 weeks after PCV13, followed by a second 
dose of PPSV23 at least 5 years after the first dose of PPSV23. If the most 
recent dose of PPSV23 was administered before age 65 years, at age 65 
years or older, administer another dose of PPSV23 at least 8 weeks after 
PCV13 and at least 5 years after the most recent dose of PPSV23.
• Adults aged 19 years or older with cerebrospinal fluid leak or cochlear 
implant should receive PCV13 followed by PPSV23 at least 8 weeks after 
PCV13. If the most recent dose of PPSV23 was administered before age 
65 years, at age 65 years or older, administer another dose of PPSV23 at 
least 8 weeks after PCV13 and at least 5 years after the most recent dose 
of PPSV23.
• Notes: Immunocompromising conditions that are indications for 
pneumococcal vaccination are congenital or acquired immunodeficiency 
including B- or T-lymphocyte deficiency, complement deficiencies, 
and phagocytic disorders excluding chronic granulomatous disease; 
human immunodeficiency virus (HIV) infection; chronic renal failure 
and nephrotic syndrome; leukemia, lymphoma, Hodgkin disease, 
generalized malignancy, and multiple myeloma; solid organ transplant; 
and iatrogenic immunosuppression including long-term systemic 
corticosteroid and radiation therapy. Anatomical or functional asplenia 
that are indications for pneumococcal vaccination are sickle cell disease 
and other hemoglobinopathi s, congenital or acquired asplenia, splenic 
dysfunction, a d splenectomy. Pneumococcal vaccines should be given 
at least 2 weeks b fore immunosuppressive therapy r an elective 
spl nec omy, and as soon as possible to adults who are diagnosed with 
HIV nfection.
8. Hepatitis A vaccination
General infor ation
• Adults who seek protection from hepatitis A virus infection may receive 
a 2-dose series of single antigen hepatitis A vaccine (HepA) at either 0 
and 6–12 months (Havrix) or 0 and 6–18 months (Vaqta). Adults may 
also receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) as a 3-dose series at 0, 1, and 6 months. Acknowledgment of a 
specific risk factor by those who seek protection is not needed.
Special populations
• Adults with any of the following indications should receive a HepA 
series: have chronic liver disease, receive clotting factor concentrates, 
en who have sex with men, use injection or non-injection drugs, 
or work with hepatitis A virus-infecte  primates or in a hepatitis A 
re arch laboratory setting.
• Adults who ravel in countries with high or intermediate levels of 
endemic hepatitis A fection or anticipate close personal contact 
with an i ternational adoptee, e.g., reside in the same hou ehold or 
regularly babysit, from a country with high or intermediate level of 
end mic hepatitis A infecti n within the first 60 days of arrival in the 
United States sh uld receive a HepA series.
9. Hepatitis B vac ination
General information
• Adults who seek protection from hepatitis B virus infection may 
receive a 3-dose series of single-antigen hepatitis B vaccine (HepB) 
(Engerix-B, Recombivax HB) at 0, 1, and 6 months. Adults may also 
receive a combined hepatitis A and hepatitis B vaccine (HepA-HepB) 
(Twinrix) at 0, 1, and 6 months. Acknowledgment of a specific risk 
factor by t ose who s ek protecti  is not needed.
Special populations
• Adults at risk for hepatitis B virus infection by sexual exposure should 
receive a HepB series, including sex partners of hepatitis B surf ce 
antigen (HBsAg)-positive persons, sexually active persons who 
are not in a mutually monogamous relationship, persons seeking 
evaluation or treatment for a sexually transmitted infection, and men 
who have sex with en (MSM).
• Adults at risk for hepatitis B virus infection by percutaneous or 
mucosal exposure to blood should receive a HepB series, including 
adults who are recent or current users of injection drugs, household 
contacts of HBsAg-positive persons, residents and staff of facilities 
for develop entally disabled persons, incarcerated, healthcare 
and public safety workers at risk for exposure to blood or blood-
contaminated body fluids, younger than age 60 years with diabetes 
mellitus, and age 60 years r ol er with diabetes mellitus t the 
discretion of th  treating clinician.
• Adul s with chronic liver disease including, but not limited to, 
hepatitis C virus infection, cirrhosis, fatty liver diseas , alcoholic liver 
disease, autoimmune hepatitis, and an alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) level greater than twice 
the upper limit of normal should receive a HepB series.
• Adults with end-stag  renal disease includi g thos  on pre-dialysis 
care, hemodialysis, peritoneal dialysis, d home dialysis should 
receive a HepB series. Adults on hem dialysis should receive a 
3-dose series of 40 µg Recombivax HB at 0, 1, a d 6 months or a 
4-dose series of 40 µg Engerix-B at 0, 1, 2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection should 
receive a HepB series.
• Pregnant women who are at risk for hepatitis B virus infection 
during pregnancy, e.g., having more than one sex partner during 
the previous six months, been evaluated or treated for a sexually 
transmitted infection, recent or current injection drug use, or had an 
HBsAg-positive sex partner, should receive a HepB series.
• International travelers to regions with high or intermediate levels of 
endemic hepatitis B virus infection should receive a HepB series.
• Adults in the following settings are assumed to be at risk for 
hepatitis B virus infection and should receive a HepB series: sexually 
transmitted disease treatment facilities, HIV testing and treatment 
facilities, facilities providing drug-abuse treatment and prevention 
services, healthcare settings targeting services to persons who 
inject drugs, correctional facilities, healthcare settings targeting 
services to MSM, hemodialysis facilities and end-stage renal disease 
programs, and institutions and nonresidential day care facilities for 
developmentally disabled persons.
10. Menin oc c al vaccination
Special populations
• Adults with anatomical or functional asplenia or persistent complement 
component deficiencies should receive a 2-dose primary series of 
serogroups A, C, W, and Y meningococcal conjugate vaccine (MenACWY) 
at least 2 months apart and revaccinate every 5 years. They should also 
receive a series of serogroup B meningococcal vaccine (MenB) with either 
a 2-dose series of MenB-4C (Bexsero) at least 1 month apart or a 3-dose 
series of MenB-FHbp (Trumenba) at 0, 1–2, and 6 months.
• Adults with human immunodeficiency virus (HIV) infection who have 
not been previously vaccinated should receive a 2-dose primary series of 
MenACWY at least 2 months apart and revaccinate every 5 years. Those 
who previously received 1 dose of MenACWY should receive a second 
dose at least 2 months after the first dose. Adults with HIV infection are 
not routinely recommended to receive MenB because meningococcal 
disease in this population is caused primarily by serogroups C, W, and Y.
• Microbiologists who are routinely exposed to isolates of Neisseria 
meningitidis should receive 1 dose of MenACWY and revaccinate every 5 
years if the risk for infection remains, and either a 2-dose series of MenB-
4C at le st 1 month apart or a 3-dose series of MenB-FHbp at 0, 1–2, and 
6 months.
• Adults at risk because of a meningococcal disease outbreak should 
receive 1 dose of MenACWY if the outbreak is attributable to serogroup 
A, C, W, or Y, or either a 2-dose series of MenB-4C at least 1 month apart or 
a 3-dose series of MenB-FHbp at 0, 1–2, and 6 months if the outbreak is 
attributable to serogroup B.
• Adults who travel to or live in countries with hyperendemic or epidemic 
meningococcal disease should receive 1 dose of MenACWY and 
revaccinate every 5 years if the risk for infection remains. MenB is not 
routinely indicated because meningococcal disease in these countries is 
generally not caused by serogroup B.
• Military recruits should receive 1 dose of MenACWY and revaccinate 
every 5 years if the increased risk for infection remains.
• First-year college students aged 21 years or younger who live in 
residence halls should receive 1 dose of MenACWY if they have not 
received MenACWY at age 16 years or older.
• Young adults aged 16 through 23 years (preferred age range is 16 
through 18 years) who are healthy and not at increased risk for serogroup 
B meningococcal disease (described above) may receive either a 2-dose 
series of MenB-4C at least 1 month apart or a 2-dose series of MenB-
FHbp at 0 and 6 months for short-term protection against most strains of 
serogroup B meningococcal disease. 
• For adults aged 56 years or older who have not previously received 
serogroups A, C, W, and Y meningococcal vaccine and need only 1 
dose, meningococcal polysaccharide serogroups A, C, W, and Y vaccine 
(MPSV4) is preferred. For adults who previously received MenACWY 
or anticipate receiving multiple doses of erogroups A, C, W, and Y 
meningococcal vaccine, MenACWY is preferred. 
• Notes: MenB-4C and MenB-FHbp are no  interchangeable, i.e., the same 
vaccine should be used for all doses to compl te the s ies. There is no 
recommendation for MenB revaccinati n at this time. M nB may be 
administer d at the same time as MenACWY but at a different an tomic 
site, if feasibl .
11.  Haemophilus influenzae type b vaccination
Special populatio s
• Adults who hav  anatomical or functional asplenia or sickle cell disease, 
or ar  undergoing elective splenectomy should receive 1 dose of 
Haemophilus influenzae type b conjugat  vacci e (Hib) if th y have not 
previously received Hib. Hib should b  administer d at least 14 days 
before splenectomy.
• Adults with a atopoietic stem cell transplant (HSCT) should receive 
3 doses of Hib in at least 4 week intervals 6–12 months fter transplant 
regardless of their Hib history.
• Notes: Hib is not routinely recommended for adults with human 
immunodeficiency virus infection because their risk for Haemophilus 
influenzae type b infection is low.
